Over the last few years, progress has been made in the search for new anti-TB compounds . The current drug pipeline shows ten drug candidates under preclinical and early phase 1 development for drug-sensitive and/or drug-resistant tuberculosis. Regarding MDR-TB, the drug pipeline presents six compounds in phase 2 and 3 trials. Bedaquiline (Sirturo®, Janssen Therapeutics, Titusville, NJ, USA) and delamanid (Deltyba®, Otsuka Pharmaceutical, Tokyo, Japan) remain in trial phase 3; despite their approval in several countries justified by the emergency caused by MDR-TB. Sutezolid and pretomanid are, in phase 2 and 3 trials, respectively. The repurposed drugs clofazimine and levofloxacin are in phase 3 and 2 trials, respectively .